BioSenic provides first quarter 2023 business update

BioSenic (Euronext Brussels and Paris: BIOS), the clinical stage company specializing in serious autoimmune and inflammatory diseases and cell repair, today announces its business update for the first quarter, ended 31 March 2023. Key highlights. Strengthening of Executive Committee and Board of Directors with the ...

Related Keywords

Belgium ,Paris ,France General ,France ,Mont Saint Guibert ,Waals Gewest , ,Biosenic Group ,Bonds ,Euronext Brussels ,Executive Committee ,Chief Scientific Officer ,Chief Medical Officer ,Yves Sagot ,Marketing Authorization ,Marketing Authorization Application ,Convertible Bonds ,Senic Group ,Arsenic Trioxide ,Host Disease ,Systemic Sclerosis ,Louvain La Neuve Science Park ,Mesenchymal Stromal Cells ,Graft Versus Host Disease ,Systemic Lupus ,